Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 4 3Phase 1 2Phase NA 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 3

Conditions

Lymphoma, T-Cell, Cutaneous 3Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell 1

Interventions

Cyclophosphamide 27Vincristine 24Dexamethasone 22Rituximab 21Methotrexate 21Cytarabine 21Mercaptopurine 16Doxorubicin 15Etoposide 13Asparaginase 13Daunorubicin 12Prednisone 10Prednisolone 10Granulocyte Colony-Stimulating Factor 10Ifosfamide 8Idarubicin 8fludarabine 7pegylated granulocyte colony-stimulating factor 6Thioguanine 6Teniposide 6Vindesine 5Brentuximab Vedotin 5ibrutinib 4fludarabine phosphate 4Stem Cell Transplantation 4Gemcitabine 4Cisplatin 4Aprepitant 4zanubrutinib 3prednylidene 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × denileukin diftitox × Lymphoid × Clear all
NCT00050999 2008-03-05

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

Eisai Inc.

Phase 4 Completed
195 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00051012 2008-03-05

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Eisai Inc.

Phase 4 Completed
86 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00211198 2008-03-05

Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

Eisai Inc.

Phase 4 Completed
60 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡